Archives: Agenda

• A key digital transformation currently in live trials is the shift from traditional paper-based relabeling to the use of digital display labels in clinical trial settings.
• The integration of digital display labels marks a significant advancement in clinical trial operations, offering enhanced efficiency and flexibility.
• As this technology evolves and gains broader adoption, it is poised to transform clinical trial management—particularly in remote monitoring, adaptive trial design, and patient engagement.
• This session will examine the limitations of traditional relabeling methods, highlight the benefits of digital display labels, and discuss their potential to reshape the future of clinical research and healthcare innovation.

• Optimize employ effort
• Minimize waste and risk
• Appreciate significant savings
• Sustainably friendly

• Evaluating new initiatives to speed up study start up and site activation
• Streamlining trial start up and site activation by establishing strong communication
• Implementing and executing new processes across your company for easy and effective study start up

• Maintaining patient centricity in your trial to positively impact recruitment and engagement
• Working with patients, caregivers and advocacy groups to establish better patient support systems throughout trial participation
• Best practice in prioritizing patient needs in clinical trial design

• Lessons from working in a resource-constrained biotech environment conducting sponsored trials.
• How a strategically structured and collaborative Investigator-Sponsored Trial (IST) program helped generate valuable data to support and expand the pipeline.
• The role of strong relationships with KOLs and a responsive clinical development team in motivating high-quality IST proposals.

Examples of ISTs used to:

• Explore new indications (within and beyond oncology)
• Test novel combinations involving our investigational product

Operational models:

• Company-funded ISTs as a cost-effective alternative to sponsored trials
• Fully externally funded ISTs supported by institutional or government grants

• The importance of alignment between Clinical Development and Clinical Operations to support and oversee ISTs effectively.
• How ISTs enabled continuous data generation and scientific momentum, even while internal resources were focused on a single lead program.

Visit our exhibitors’ booths throughout the day and collect stamps in order to enter our Prize Draw and be in for a chance of winning Apple devices or Amazon vouchers. The Prize Draw will take place in the Exhibition Hall, make sure you don’t miss out!

In the complex world of clinical research, even meticulously planned trials can face unexpected hurdles that threaten to derail progress and encounter obstacles beyond the capabilities of a small-scale Clinical Research Organization (CRO). When studies falter, a well-executed rescue strategy with an experienced global CRO becomes crucial. Drawing from Parexel’s extensive rescue-trial experience, this presentation unveils the blueprint for successful clinical trial transitions, focusing on four key phases:

• Strategic Initiation & Planning – establishing a robust framework and standardized processes
• Comprehensive Preparation & Due Diligence – ensuring stakeholder alignment on transition plans and timelines  – Conducting thorough documentation review and gap analysis
• Adaptive Execution & Transfer – How to operationalize a study transfer – Anticipating challenges and employing agile governance for real-time course corrections
• Effective Closure & Delivery – defining clear transition thresholds and success metrics  – Ensuring continuity and maintaining data integrity throughout the process